Zacks Investment Research
06 Jul 2026, 23:17 UTC · 8w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Boston Scientific currently holds a Zacks Rank of #4 (Sell). — A 'Sell' rating from a quantitative ranking system typically signals negative near-term price momentum or deteriorating fundamentals.
-0.60Boston Scientific's forecasted EPS for the upcoming quarter is $0.83, representing a 10.67% year-over-year increase. — Projected double-digit earnings growth is fundamentally positive for the stock's valuation.
+0.30The Zacks Consensus EPS estimate for Boston Scientific has decreased by 0.32% over the past month. — Downward revisions by analysts often precede negative price action or indicate a cooling of growth expectations.
-0.20Continue reading
6 related stories
Top 3 movers · tap to explore
Boston Scientific is scheduled to release its next earnings report on July 29, 2026. — Earnings dates create volatility catalysts, though the date itself is neutral until results are released.
Which stocks this story touches
The stock is down, underperforming its sector and the S&P 500, and currently holds a Zacks Rank of #4 (Sell).
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1d ago
